Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000511 | 0.85 | GAA (0.59) | GAAMAPK1ALDH1A1TDP1HTT | |
| SCHEMBL13073616 | 0.84 | ACHE (0.67) | GAAMAPK1ALDH1A1TDP1HTT | |
| SCHEMBL14593599 | 0.84 | GAA (0.58) | GAAMAPK1ALDH1A1TDP1HTT | |
| SCHEMBL19106730 | 0.84 | RECQL (0.54) | GAAMAPK1ALDH1A1POLBPIK3CD | |
| SCHEMBL12424623 | 0.83 | GAA (0.67) | GAAMAPK1ALDH1A1TDP1HTT | |
| SCHEMBL29995238 | 0.82 | GAA (0.62) | GAAMAPK1ALDH1A1TDP1HTT | |
| SCHEMBL21183264 | 0.82 | GAA (0.62) | GAAMAPK1ALDH1A1TDP1HTT | |
| SCHEMBL2603247 | 0.82 | ACHE (0.68) | ALDH1A1POLBMEN1KMT2AHPGD | |
| SCHEMBL9763711 | 0.82 | PKM (0.74) | MAPK1ALDH1A1TDP1PKMPOLB | |
| SCHEMBL2427413 | 0.81 | GAA (0.61) | GAAMAPK1ALDH1A1TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-9126973-B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150099748-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-04-09 | — | — | US | disclosed |
| US-8536185-B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| US-8450326-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20130079375-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | GAA 1030/4885MAPK1 517/4885ALDH1A1 361/4885 |
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | GAA 1585/4885MAPK1 1549/4885ALDH1A1 2131/4885 |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | GAA 996/4885MAPK1 1118/4885ALDH1A1 3835/4885 |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | GAA 4832/4885MAPK1 64/4885ALDH1A1 3540/4885 |
| US-20130079375-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | GAA 1585/4885MAPK1 1549/4885ALDH1A1 2131/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | GAA 3921/4885MAPK1 1/4885ALDH1A1 1430/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | GAA 959/4885MAPK1 477/4885ALDH1A1 285/4885 |
| US-20150099748-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | GAA 1585/4885MAPK1 1549/4885ALDH1A1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.